Monitoring visits completed in Ritter's late-stage study of lead product candidate RP-G28, top-line data expected in Q1; shares up 24%

|About: Ritter Pharmaceuticals (RTTR)|By:, SA News Editor

Thinly traded nano cap Ritter Pharmaceuticals (RTTR +24.1%) heads north on a 20x surge in volume in response to its announcement that the last patient has been dosed and all monitoring visits have been completed its 377-subject Phase 2b/3 study assessing lead product candidate RP-G28 for the treatment of lactose intolerance. Top-line results should be available next quarter.

RP-G28, a highly purified galactooligosaccharide, is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. If approved, it will be the first drug cleared by the FDA for the indication.